New antibody drug takes on advanced cancers in first human trial

NCT ID NCT05378425

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new drug called NTX-1088, which targets a protein on cancer cells, either alone or combined with the immunotherapy pembrolizumab. The study involves 90 people with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe dose and to see if the treatment can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
NTX-1088 (a lab-made antibody targeting a protein on cancer cells) and pembrolizumab (an immunotherapy drug that helps the immune system attack cancer)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early (Phase 1) and small study, so the drug may not shrink tumors or could cause side effects. Success in this trial does not guarantee it will work for most patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Hadassah Medical Center

    Jerusalem, 9574425, Israel

  • Maria Skłodowska-Curie National Research Institute of Oncology

    Warsaw, Poland

  • Ochsner Clinic Foundation

    New Orleans, Louisiana, 70121, United States

  • Sheba Medical Center

    Ramat Gan, 5262131, Israel

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.